<i>PIK3CA</i> Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer - Concepedia

Concepedia

Publication | Open Access

<i>PIK3CA</i> Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer

DOI Full Paper Access

217

Citations

31

References

2015

Year

Ian J. Majewski, Paolo Nucíforo, Lorenza Mittempergher, Astrid J Bosma, Holger Eidtmann, Eileen Holmes, Christos Sotiriou, Debora Fumagalli, José Jiménez, Claudia Aura,

Journal of Clinical Oncology

Abstract

Activating mutations in PIK3CA predicted poor pCR in patients with HER2-positive breast cancer treated with neoadjuvant therapies that target HER2. Consequently, the combination of anti-HER2 agents and PI3K inhibitors is being investigated.

References

	Year	Citations

Page 1